A. Rydlewski

Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived

M. Minden, Steven M. Chan, A. Schimmer, 2016, Leukemia & lymphoma.

Unsuspected Caffeine Toxicity Complicating Theophylline Therapy

R. Levy, S. A. Iversen, D. Gertner, 1984, Human toxicology.

AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.

M. Minden, Steven M. Chan, S. Kamel‐Reid, 2018, Leukemia research.

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy

A. Schimmer, K. Yee, E. Atenafu, 2018, Supportive Care in Cancer.

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

M. Minden, A. Schimmer, K. Yee, 2015 .